Advanced Search
ZHAO Yuekui, TANG Shanshan, ZHANG Yanfeng, ZONG Li, JIN Liang. Engineered mesenchymal stem cells as targeting therapeutic carriers in cancer therapy[J]. Journal of China Pharmaceutical University, 2016, 47(2): 134-139. DOI: 10.11665/j.issn.1000-5048.20160202
Citation: ZHAO Yuekui, TANG Shanshan, ZHANG Yanfeng, ZONG Li, JIN Liang. Engineered mesenchymal stem cells as targeting therapeutic carriers in cancer therapy[J]. Journal of China Pharmaceutical University, 2016, 47(2): 134-139. DOI: 10.11665/j.issn.1000-5048.20160202

Engineered mesenchymal stem cells as targeting therapeutic carriers in cancer therapy

  • Mesenchymal stem cells(MSCs)were derived from the early development stage of mesoderm and ectoderm and considered as one of the important members of stem cells family. Besides that, MSCs can be isolated easily and don′t have a limitation of moral and ethical problems. Moreover, MSCs can be expanded in vitro which make it possible to use in industrial preparation. Moreover, MSCs possess low immunogenicity and has the ability to home to damaged tissues, tumors, and metastases. Therefore, MSCs possess a set of fairly unique properties which make them ideally suited for clinical applications. This review summarizes the main properties of MSCs and its new progress in drug delivery system in the field of cancer therapy as a basis of further utility of engineered MSCs in the design of targeting drug delivery system.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return